Page last updated: 2024-08-22

(1S,2R)-tranylcypromine and Acute Myelogenous Leukemia

(1S,2R)-tranylcypromine has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lan, F; Liu, R; Xu, S; Xu, Y; Zha, X; Zhou, C; Zhu, Q	1

Other Studies

1 other study(ies) available for (1S,2R)-tranylcypromine and Acute Myelogenous Leukemia

Article	Year
Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia. Bioorganic & medicinal chemistry, 2018, 09-15, Volume: 26, Issue:17 Topics: Antineoplastic Agents; Barbiturates; Cell Line, Tumor; DNA Methylation; Enzyme Inhibitors; Histone Demethylases; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Spectrum Analysis	2018

Article

Year

Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.

Bioorganic & medicinal chemistry, 2018, 09-15, Volume: 26, Issue:17

Topics: Antineoplastic Agents; Barbiturates; Cell Line, Tumor; DNA Methylation; Enzyme Inhibitors; Histone Demethylases; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Spectrum Analysis

2018